Milestone Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of cardiovascular medicines. The company is developing etripamil, a novel channel blocker, which is in Phase III clinical trial for the treatment of paroxysmal supraventricular tachycardia in the United States and Canada; and Phase II clinical trial for the treatment of atrial fibrillation and rapid ventricular rate. It has a license and collaboration agreement with Ji Xing Pharmaceuticals to develop and commercialize etripamil …
Over the last 12 months, insiders at Milestone Pharmaceuticals Inc. have bought $0 and sold $0 worth of Milestone Pharmaceuticals Inc. stock.
On average, over the past 5 years, insiders at Milestone Pharmaceuticals Inc. have bought $8.88M and sold $10.86M worth of stock each year.
There was no buying activity among insiders over the last 12 months.
The last purchase of 7,000 shares for transaction amount of $32,830 was made by Bharucha David (Chief Medical Officer) on 2022‑12‑05.
2022-12-05 | Chief Medical Officer | 7,000 0.0162% | $4.69 | $32,830 | -27.47% | |||
2022-12-01 | Chief Medical Officer | 3,000 0.007% | $4.86 | $14,580 | -29.01% | |||
2022-10-21 | director | 4,000 0.0096% | $5.26 | $21,040 | -28.57% | |||
2022-10-20 | director | 10,000 0.0232% | $5.20 | $52,000 | -30.21% | |||
2022-10-20 | director | 10,000 0.0236% | $5.29 | $52,900 | -30.21% | |||
2022-10-19 | director | 15,000 0.0349% | $4.93 | $73,950 | -26.01% | |||
2022-10-19 | director | 15,000 0.0376% | $5.32 | $79,800 | -26.01% | |||
2022-09-07 | Sale | 1.56M 3.6651% | $8.71 | $13.56M | -56.03% | |||
2022-09-07 | 1.56M 3.6651% | $8.71 | $13.56M | -56.03% | ||||
2022-05-31 | 5,000 0.0118% | $5.60 | $28,000 | -19.25% | ||||
2020-07-29 | Sale | 10 percent owner | 500,000 1.5968% | $8.32 | $4.16M | -22.80% | ||
2020-07-28 | Sale | 10 percent owner | 19,863 0.0675% | $8.10 | $160,890 | -15.61% | ||
2020-03-19 | 10 percent owner | 5,870 0.02% | $10.87 | $63,804 | -47.34% | |||
2020-03-18 | 10 percent owner | 2,705 0.0091% | $10.36 | $28,029 | -45.49% | |||
2020-03-02 | 10 percent owner | 78,263 0.3217% | $18.95 | $1.48M | -63.55% | |||
2020-01-13 | 10 percent owner | 270,000 1.0575% | $16.25 | $4.39M | -59.47% | |||
2019-12-31 | director | 21,438 0.0846% | $15.50 | $332,340 | -56.84% | |||
2019-12-30 | director | 1,333 0.0054% | $15.48 | $20,638 | -55.51% | |||
2019-11-25 | Sale | 10 percent owner | 240,000 0.8778% | $16.00 | $3.84M | -57.86% | ||
2019-11-20 | 10 percent owner | 400,000 1.4001% | $16.00 | $6.4M | -58.59% |
RTW INVESTMENTS, LP | 10 percent owner | 4315102 8.1005% | $1.78 | 13 | 0 | |
WONG RODERICK | 4315102 8.1005% | $1.78 | 1 | 1 | <0.0001% | |
Novo Holdings A/S | 10 percent owner | 2434470 4.5701% | $1.78 | 1 | 1 | |
BDC CAPITAL INC. | 10 percent owner | 2388088 4.483% | $1.78 | 1 | 0 | |
FONDS DE SOLIDARITE DES TRAVAILLEURS DU QUEBEC | 10 percent owner | 2254920 4.233% | $1.78 | 1 | 2 |
BlackRock | $8.9M | 9.33 | 4.97M | +51.99% | +$3.04M | <0.0001 | |
RTW Investments, LP | $5.83M | 6.11 | 3.26M | 0% | +$0 | 0.09 | |
Millennium Management LLC | $5.11M | 5.36 | 2.86M | +91.08% | +$2.44M | <0.01 | |
Alta Fundamental Advisers Llc | $4.24M | 4.45 | 2.37M | +41.88% | +$1.25M | 2.2 | |
Lion Point Capital LP | $4.12M | 4.32 | 2.3M | +39.39% | +$1.16M | 7.98 |